RT Journal Article
SR Electronic
T1 Calcitriol treatment is safe and increases frataxin levels in Friedreich Ataxia patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.10.28.23297713
DO 10.1101/2023.10.28.23297713
A1 Alemany Perna, Berta
A1 Tamarit, Jordi
A1 López Domínguez, Daniel
A1 Quiroga-Varela, Anna
A1 Merchan Ruiz, Miguel
A1 Ramió i Torrentà, Lluís
A1 Genís, David
A1 Ros, Joaquim
YR 2023
UL http://medrxiv.org/content/early/2023/10/30/2023.10.28.23297713.abstract
AB Background Calcitriol, the active form of vitamin D (also known as 1,25-dihydroxycholecalciferol), improves the phenotype and increases frataxin levels in cell models of Friedreich Ataxia (FRDA).Methods Based on these results, we started a pilot clinical trial in which a dose of 0.25mcg/24h was administered to 15 FRDA patients for a year. Evaluations of neurological function changes (SARA scale, 9-HPT, 8-MWT, PATA test) and quality of life (Barthel Scale and SF-36 quality of life questionnaire) were performed. Frataxin amounts were measured in isolated platelets obtained from these FRDA patients, from heterozygous FRDA carriers (relatives of the FA patients) and from non-heterozygous sex and age matched controls.Results Although the patients did not experience any observable neurological improvement, there was a statistically significant increase in frataxin levels from initial values, 5,6 pg/μg, to 7,0 pg/μg after 12 months. Differences in frataxin levels referred to total protein amounts were observed amongst sex and age matched controls (18.11 pg/μg), relative controls (10.07 pg/μg), and FRDA patients (5.71 pg/μg). The treatment was well tolerated by most patients, and only some of them experienced minor adverse effects at the beginning of the trial.Conclusion Calcitriol dosage used (0.25mcg/24h) is safe for FRDA patients and it increases frataxin levels. We cannot rule out that higher doses administered longer could yield neurological benefits.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04801303Funding StatementThis study was funded by FEDAES (Federacion de Ataxias de Espana) and by Ministerio de Ciencia e Innovacion (Spain), grant number PID2020-118296RB-I00.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The trial received the approval of the AEMPS (Spanish Agency for Medication and Healthcare Products) with the EudraCT number 2020-001092-32, and it also received the approval of the hospital Local Committee CEIM Girona (Comite d'Etica de la Investigacio Clinica) with the number 202010. The trial was registered in Clinicaltrial.gov (identifier NCT04801303)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors: balemany.girona.ics{at}gencat.cat